GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Total Payout Ratio

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Total Payout Ratio : 0.00 (As of May. 26, 2024)


View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

CERo Therapeutics Holdings's current Total Payout Ratio is 0.00.

CERo Therapeutics Holdings Total Payout Ratio Historical Data

The historical data trend for CERo Therapeutics Holdings's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings Total Payout Ratio Chart

CERo Therapeutics Holdings Annual Data
Trend Dec21 Dec22
Total Payout Ratio
- -

CERo Therapeutics Holdings Semi-Annual Data
Dec21 Dec22
Total Payout Ratio - -

Competitive Comparison of CERo Therapeutics Holdings's Total Payout Ratio

For the Biotechnology subindustry, CERo Therapeutics Holdings's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CERo Therapeutics Holdings's Total Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CERo Therapeutics Holdings's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where CERo Therapeutics Holdings's Total Payout Ratio falls into.


CERo Therapeutics Holdings Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

CERo Therapeutics Holdings's Total Payout Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0 + 0) / -11.829
=0.00

CERo Therapeutics Holdings's Total Payout Ratio for the quarter that ended in Dec. 2022 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0 + 0) / -11.829
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CERo Therapeutics Holdings Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Total Payout Ratio
Comparable Companies
Traded in Other Exchanges
N/A
Address
201 Haskings Way, Suite 230, San Francisco, CA, USA, 94080
Website
https://www.cero.bio
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Headlines

From GuruFocus

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

By Business Wire • 03-07-2024